LGND

Ligand Pharmaceuticals Incorporated (LGND) ESG Analysis Analysis (2026)

Invetso Score: 7.3/10 — Strong · Last Updated: 2026-08-01

Environmental

LGND's R&D intensity supports lower direct environmental footprint than manufacturing-heavy peers, because value creation is more science-led than asset-intensive.

The company appears less exposed to energy, water, and waste risks than larger industrial peers, since its capital base is comparatively light and research-oriented.

Environmental disclosure is harder to verify from the provided data alone, which limits peer differentiation versus firms with more explicit climate and resource reporting.

No material environmental controversy is indicated in the supplied metrics, so relative ESG positioning remains stronger than peers with heavier operational emissions exposure.

Social

LGND's high R&D spend relative to revenue suggests a skilled, knowledge-based workforce, which typically supports stronger human-capital quality than labor-intensive peers.

Stock-based compensation is elevated versus revenue, which can align employees with long-term value creation but may also pressure retention perceptions relative to peers.

The business model is less dependent on large frontline workforces than many industrial or healthcare-services peers, reducing exposure to workplace safety and labor-intensity risks.

No social controversy is evident in the provided inputs, leaving LGND positioned above peers with more frequent labor, product, or access-related social issues.

Governance

LGND's leverage metrics are manageable, but debt-to-equity above one is less conservative than many peers and modestly weakens governance discipline.

Stock-based compensation at 18.3% of revenue is high, which can dilute shareholders and signal weaker compensation efficiency than better-aligned peers.

The very high gross margin indicates strong pricing and operating control, yet it does not by itself offset the governance scrutiny created by compensation intensity.

No evidence of severe governance failure is present, but relative positioning remains mid-pack because capital-allocation discipline appears less robust than top-tier peers.

Overall Score

LGND screens as a strong relative ESG name versus peers, led by a science-based, lower-footprint operating model and limited visible controversy, offset by middling governance discipline.

Score Driver: Knowledge-Intensive Business Model With Limited Operational ESG Exposure

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Ligand Pharmaceuticals Incorporated. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →